Reditux 500mg and 100mg Injection 1 includes Rituximab, which is classified as a monoclonal antibody. Its mechanism of action involves inhibiting DNA and RNA transcription, which is crucial for cancer cell growth. This inhibitory effect helps impede the proliferation and dissemination of cancerous and non-cancerous cells. Reditux 100 Injection 1 also intervenes in the immune system responsible for joint tissue inflammation, effectively reducing pain and inflammation. This dual action alleviates immediate symptoms, safeguards against joint damage, and impedes disease progression over time.